Predictors of Successful Yttrium-90 Radioembolization Bridging or Downstaging in Patients with Hepatocellular Carcinoma

Table 5

Adverse events status after Y90-RE, per Common Terminology Criteria for Adverse Events version 5.0.

Characteristic	Outside Milan criteria		Inside Milan criteria		value	Unfavorable response		Favorable response		value
Clinical symptoms present	Grade 1/2	Grade 3/4	Grade 1/2	Grade 3/4		Grade 1/2	Grade 3/4	Grade 1/2	Grade 3/4
Encephalopathy	0 (0%)	0 (0%)	1 (2%)	0 (0%)	1	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1
Ascites	20 (26%)	0 (0%)	5 (8%)	2 (3%)	0.06	18 (33%)	0 (0%)	7 (9%)	2 (2%)	0.1
Fatigue	28 (36%)	1 (1%)	15 (25%)	0 (0%)	0.7	19 (25%)	1 (2%)	24 (9%)	0 (0%)	0.5
Abdominal pain	24 (22%)	1 (1%)	15 (25%)	1 (2%)	0.6	16 (29%)	2 (4%)	23 (28%)	0 (0%)	0.2
Nausea	9 (12%)	2 (3%)	10 (17%)	0 (0%)	0.3	9 (17%)	2 (4%)	10 (12%)	0 (0%)	0.3
Vomiting	2 (3%)	0 (0%)	4 (6%)	0 (0%)	1	2 (4%)	0 (0%)	4 (5%)	0 (0%)	1
Anorexia	8 (10%)	1 (1%)	6 (10%)	0 (0%)	0.6	5 (9%)	1 (2%)	9 (11%)	0 (0%)	0.4
Constipation	4 (5%)	0 (0%)	0 (0%)	0 (0%)	1	2 (4%)	0 (0%)	2 (2%)	0 (0%)	1
Fever	1 (1%)	0 (0%)	0 (0%0	0 (0%)	1	0 (0%)	0 (0%)	1 (1%)	0 (0%)	1
	Inside Milan criteria		Outside Milan criteria		value	Favorable response		Unfavorable response		value
Laboratory levels	Grade 1/2	Grade 3/4	Grade 1/2	Grade 3/4		Grade 1/2	Grade 3/4	Grade 1/2	Grade 3/4
INR	21 (28%)	1 (1%)	13 (22%)	1 (2%)	0.6	13 (24%)	1 (2%)	21 (26%)	1 (1%)	0.6
Aspartate transaminase	46 (61%)	3 (4%)	29 (49%)	1 (2%)	0.5	33 (61%)	2 (4%)	42 (52%)	2 (2%)	0.6
Alkaline phosphatase	49 (64%)	1 (1%)	28 (47%)	0 (0%)	0.6	35 (65%)	1 (%)	42 (52%)	0 (0%)	0.5
Alanine transaminase	15 (20%)	1 (1%)	13 (22%)	0 (0%)	0.6	9 (16%)	0 (0%)	19 (23%)	1 (1%)	0.7
Total bilirubin	24 (21%)	1 (1%)	23 (38%)	1 (2%)	0.7	21 (39%)	0 (0%)	28 (32%)	2 (2%)	0.3
Creatinine	10 (13%)	1 (1%)	7 (12%)	1 (2%)	0.7	8 (15%)	0 (0%)	9 (11%)	2 (2%)	0.3
Albumin	41 (54%)	3 (4%)	24 (41%)	0 (0%)	0.3	23 (61%)	3 (5%)	32 (39%)	0 (0%)	0.1
Sodium	31 (41%)	0 (0%)	21 (36%)	0 (0%)	1	24 (44%)	0 (0%)	28 (35%)	0 (0%)	1

INR = international normalized ratio.